Suven Life Sciences up by 5 per cent Intraday after receiving 5 Product Patents

Suven Life Sciences announced today that they secured patents in Australia, China, Europe, South Korea and USA to their New Chemical Entities (NCE’s) for CNS therapy through mechanism of action and these patents are valid until 2031, 2030, 2031, 2030 and 2031 respectively.

The granted claims of the patent include the class of selective H3 ligands discovered by Suven and they are developing therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders.

With these new patents, Suven has a total 22 granted product patents in Australia,19 granted patents from China, 17 granted patents from Europe, 17 granted patents from South Korea and 23 granted patents from USA. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. The products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” says Venkat Jasti, CEO of Suven.

This month on 1st of October 15, Suven also received one product patent each from New Zealand, Singapore and USA corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid through 2032.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products. Today after receiving 5 Product Patents Suven shares are higher by 5 per cent and trading at Rs 292.